Wesper Journal

Elevating Sleep Health in Primary Care with Wesper and GLP-1 Therapies

Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.

Transforming Sleep and Metabolic Health with GLP-1 Medications

our research

The Wesper Journal is our weekly publication dedicated to exploring sleep apnea, sleep health, and the latest updates from Wesper. Each edition offers expert insights, practical tips, and valuable resources to help you better understand and improve your sleep, empowering you to take control of your sleep health journey.